Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jaime M. Beecroft is active.

Publication


Featured researches published by Jaime M. Beecroft.


European Respiratory Journal | 2006

Enhanced chemo-responsiveness in patients with sleep apnoea and end-stage renal disease

Jaime M. Beecroft; James Duffin; Andreas Pierratos; Christopher T. Chan; Philip A. McFarlane; Patrick J. Hanly

Although sleep apnoea is very common in patients with end-stage renal disease, the physiological mechanisms for this association have not yet been determined. The current authors hypothesised that altered respiratory chemo-responsiveness may play an important role. In total, 58 patients receiving treatment with chronic dialysis were recruited for overnight polysomnography. A modified Read rebreathing technique, which is used to assess basal ventilation, ventilatory sensitivity and threshold, was completed before and after overnight polysomnography. Patients were divided into apnoeic (n = 38; apnoea/hypopnoea index (AHI) 35±22 events·h-1) and nonapnoeic (n = 20; AHI 3±3 events·h-1) groups, with the presence of sleep apnoea defined as an AHI >10 events·h-1. While basal ventilation and the ventilatory recruitment threshold were similar between groups, ventilatory sensitivity during isoxic hypoxia (partial pressure of oxygen (PO2) 6.65 kPa) and hyperoxia (PO2 19.95 kPa) was significantly greater in apnoeic patients. Overnight changes in chemoreflex responsiveness were similar between groups. In conclusion, these data indicate that the responsiveness of both the central and peripheral chemoreflexes is augmented in patients with sleep apnoea and end-stage renal disease. Since increased ventilatory sensitivity to hypercapnia destabilises respiratory control, the current authors suggest this contributes to the pathogenesis of sleep apnoea in this patient population.


Chest | 2012

Declining Kidney Function Increases the Prevalence of Sleep Apnea and Nocturnal Hypoxia

David D. M. Nicholl; Sofia B. Ahmed; Andrea H. S. Loewen; Brenda R. Hemmelgarn; Darlene Y. Sola; Jaime M. Beecroft; Tanvir C. Turin; Patrick J. Hanly

BACKGROUND Sleep apnea is an important comorbidity in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). Although the increased prevalence of sleep apnea in patients with ESRD is well established, few studies have investigated the prevalence of sleep apnea in patients with nondialysis-dependent kidney disease, and no single study, to our knowledge, has examined the full spectrum of kidney function. We sought to determine the prevalence of sleep apnea and associated nocturnal hypoxia in patients with CKD and ESRD. We hypothesized that the prevalence of sleep apnea would increase progressively as kidney function declines. METHODS Two hundred fifty-four patients were recruited from outpatient nephrology clinics and hemodialysis units. All patients completed an overnight cardiopulmonary monitoring test to determine the prevalence of sleep apnea (respiratory disturbance index ≥ 15) and nocturnal hypoxia (oxygen saturation < 90% for ≥ 12% of monitoring). Patients were stratified into three groups based on estimated glomerular filtration rate (eGFR) as follows: eGFR ≥ 60 mL/min/1.73 m(2) (n = 55), CKD (eGFR < 60 mL/min/1.73 m(2) not on dialysis, n = 124), and ESRD (on hemodialysis, n = 75). RESULTS The prevalence of sleep apnea increased as eGFR declined (eGFR ≥ 60 mL/min/1.73 m(2), 27%; CKD, 41%; ESRD, 57%; P = .002). The prevalence of nocturnal hypoxia was higher in patients with CKD and ESRD (eGFR ≥ 60 mL/min/1.73 m(2), 16%; CKD, 47%; ESRD, 48%; P < .001). CONCLUSIONS Sleep apnea is common in patients with CKD and increases as kidney function declines. Almost 50% of patients with CKD and ESRD experience nocturnal hypoxia, which may contribute to loss of kidney function and increased cardiovascular risk.


Intensive Care Medicine | 2008

Sleep monitoring in the intensive care unit: comparison of nurse assessment, actigraphy and polysomnography

Jaime M. Beecroft; Michael Ward; Magdy Younes; Shelley Crombach; Orla M. Smith; Patrick J. Hanly

ObjectiveSleep loss and sleep disruption are common in critically ill patients and may adversely affect clinical outcomes. Although polysomnography remains the most accurate and reliable way to measure sleep, it is costly and impractical for regular use in the intensive care unit. This study evaluates the accuracy of two other methods currently used for measuring sleep, actigraphy (monitoring of gross motor activity) and behavioural assessment by the bedside nurse, by comparing them to overnight polysomnography in critically ill patients.DesignObservational study with simultaneous polysomnography, actigraphy and behavioural assessment of sleep.SettingMedical-surgical intensive care unit.Patients and participantsTwelve stable, critically ill, mechanically ventilated patients [68 (13) years, Glasgow coma scale 11 (0)].InterventionsNone.Measurements and resultsSleep was severely disrupted, reflected by decreased total sleep time and sleep efficiency, high frequency of arousals and awakenings and abnormal sleep architecture. Actigraphy overestimated total sleep time and sleep efficiency. The overall agreement between actigraphy and polysomnography was <65%. Nurse assessment underestimated the number of awakenings from sleep. Estimated total sleep time, sleep efficiency and number of awakenings by nurse assessment did not correlate with polysomnographic findings.ConclusionsActigraphy and behavioural assessment by the bedside nurse are inaccurate and unreliable methods to monitor sleep in critically ill patients.


European Respiratory Journal | 2007

Pharyngeal narrowing in end-stage renal disease: implications for obstructive sleep apnoea

Jaime M. Beecroft; V. Hoffstein; Andreas Pierratos; Christopher T. Chan; Philip A. McFarlane; Patrick J. Hanly

Sleep apnoea is common in patients with end-stage renal disease (ESRD). It was hypothesised that this is related to a narrower upper airway. Upper airway dimensions in patients with and without ESRD and sleep apnoea were compared, in order to determine whether upper airway changes associated with ESRD could contribute to the development of sleep apnoea. An acoustic reflection technique was used to estimate pharyngeal cross-sectional area. Sleep apnoea was assessed by overnight polysomnography. A total of 44 patients with ESRD receiving conventional haemodialysis and 41 subjects with normal renal function were studied. ESRD and control groups were further categorised by the presence or absence of sleep apnoea (apnoea/hypopnoea index ≥10 events·h−1). The pharyngeal area was smaller in patients with ESRD compared with subjects with normal renal function: 3.04±0.84 versus 3.46±0.80 cm2 for the functional residual capacity and 1.99±0.51 versus 2.14±0.58 cm2 for the residual volume. The pharynx is narrower in patients with ESRD than in subjects with normal renal function. In conclusion, since a narrower upper airway predisposes to upper airway occlusion during sleep, it is suggested that this factor contributes to the pathogenesis of sleep apnoea in dialysis-dependent patients.


Respiratory Physiology & Neurobiology | 2005

Overnight changes of chemoreflex control in obstructive sleep apnoea patients

Safraaz Mahamed; Patrick J. Hanly; Jonathan Gabor; Jaime M. Beecroft; James Duffin

We hypothesized that the numerous episodes of hypoxia, hypercapnia and arousal experienced by obstructive sleep apnoea (OSA) patients induce overnight changes in respiratory chemoreflexes. A modification of the Read rebreathing technique assessed chemoreflex characteristics in the evening and the morning of patients undergoing diagnostic assessment for OSA in a clinical sleep laboratory. Two groups were studied: those with apnoea-hypopnoea indices (AHI) greater than 30 composed the OSA group (n = 12), and those with AHI indices less than 10 composed the non-OSA group (n = 12). There was a significant (approximately 30%) overnight increase in chemoreflex sensitivities, without changes in thresholds, in the OSA group. In the non-OSA group there was a significant overnight reduction in chemoreflex thresholds (approximately 5%), without changes in sensitivities. We suggest that these changes affect the stability of the chemoreflex control system in opposite ways as the night proceeds: destabilizing breathing for patients in the OSA group, and stabilising breathing for patients in the non-OSA group.


Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine | 2012

Clinical presentation of obstructive sleep apnea in patients with chronic kidney disease.

David D. M. Nicholl; Sofia B. Ahmed; Andrea H. S. Loewen; Brenda R. Hemmelgarn; Darlene Y. Sola; Jaime M. Beecroft; Tanvir Chowdhury Turin; Patrick J. Hanly

BACKGROUND Obstructive sleep apnea (OSA) is an important and common comorbidity in patients with chronic kidney disease (CKD). However, few studies have addressed how OSA presents in this patient population and whether it is clinically apparent. OBJECTIVE The objectives of this study were to determine if the prevalence and severity of sleep related symptoms distinguished CKD patients with OSA from those without apnea, and whether the clinical presentation of OSA in CKD patients differed from the general OSA population. METHODS One hundred nineteen patients were recruited from outpatient nephrology clinics. All patients completed a sleep history questionnaire, the Epworth Sleepiness Scale (daytime sleepiness, ESS > 10), the Pittsburgh Sleep Quality Index (poor sleep quality, PSQI > 5), and underwent overnight cardiopulmonary monitoring for determination of sleep apnea (respiratory disturbance index ≥ 15). CKD patients with OSA (n = 46) were compared to (1) CKD patients without OSA (n = 73) and (2) OSA patients without CKD (n = 230) who were referred to the sleep centre. RESULTS The prevalence of OSA symptoms and PSQI scores did not differ between CKD patients with OSA and CKD patients without apnea. Although the prevalence of daytime sleepiness was higher in CKD patients with OSA compared to CKD patients without apnea (39% vs. 19%, p = 0.033), both daytime sleepiness and other symptoms of sleep apnea were considerably less frequent than in OSA patients without a history of kidney disease. CONCLUSIONS The presence of OSA in patients with CKD is unlikely to be clinically apparent. Consequently, objective cardiopulmonary monitoring during sleep is required to reliably identify this comorbidity.


Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine | 2013

Diagnostic value of screening instruments for identifying obstructive sleep apnea in kidney failure.

David D. M. Nicholl; Sofia B. Ahmed; Andrea H. S. Loewen; Brenda R. Hemmelgarn; Darlene Y. Sola; Jaime M. Beecroft; Tanvir Chowdhury Turin; Patrick J. Hanly

BACKGROUND Patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) have a high prevalence of obstructive sleep apnea (OSA) that can have significant clinical implications. An accurate clinical screening tool for OSA that identifies patients for further diagnostic testing would assist in the identification of this comorbidity. The Berlin Questionnaire (BQ), Adjusted Neck Circumference (ANC), and STOP-BANG questionnaire are 3 such instruments that have been validated in patients with normal kidney function. OBJECTIVE The objective of this study was to determine the validity of these screening instruments in patients with CKD and ESRD, using overnight cardiopulmonary monitoring to diagnose OSA. METHODS One hundred seventy-two patients were recruited from nephrology clinics and hemodialysis units (CKD: n = 109; ESRD: n = 63). All patients completed the BQ, ANC, STOP-BANG, and overnight cardiopulmonary monitoring to diagnose OSA (respiratory disturbance index [RDI] ≥ 15). Sensitivity, specificity, positive and negative predictive values, and accuracy were calculated for the BQ, ANC, and STOP-BANG. RESULTS Obstructive sleep apnea was present in 41 CKD patients (38%) and 32 ESRD patients (51%). All screening instruments had satisfactory sensitivity (56% to 94%) but poor specificity (29% to 77%) and low accuracy (51% to 69%) in both CKD and ESRD patients with RDI ≥ 15. Using an RDI ≥ 30 yielded similar results. CONCLUSIONS Current screening questionnaires do not accurately identify patients at high risk for OSA or rule out the presence of OSA in patients with CKD and ESRD. Consequently, objective monitoring during sleep is required to reliably identify sleep apnea in these patient populations.


Nephron Clinical Practice | 2008

Improvement of periodic limb movements following kidney transplantation.

Jaime M. Beecroft; Jeffery Zaltzman; G. V. Ramesh Prasad; Galo Meliton; Patrick J. Hanly

Background/Aims: Periodic limb movements are common in patients with end-stage renal disease. Kidney transplantation significantly improves renal function and may therefore reduce periodic limb movements. We evaluated the effect of kidney transplantation on periodic limb movements in a group of patients with end-stage renal disease. Methods: Eighteen patients (aged 27–65) who were receiving dialysis and were candidates for living donor or deceased donor kidney transplantation (n = 12) or were predialysis with a suitable living donor arranged (n = 6) were recruited from the transplant clinic. Attended overnight polysomnography was performed before and after kidney transplantation. Patients were divided based on a periodic limb movement index >15 events/h during sleep. Results: Kidney transplantation was associated with a significant reduction in periodic limb movement index in all patients (8 (0–110) events/h vs. 2 (0–80) events/h) and this reduction was greatest in 7 patients with a periodic limb movement index >15 events/h (40 (24–110) events/h to 14 (1–80) events/h, p < 0.005). Conclusion: Successful kidney transplantation improves periodic limb movements in patients with end-stage renal disease. This may improve sleep quality and sleep-related quality of life in kidney transplant recipients, which should have a beneficial impact on clinical outcomes.


Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine | 2013

The prevalence of restless legs syndrome across the full spectrum of kidney disease.

Jonathan Lee; David D. M. Nicholl; Sofia B. Ahmed; Andrea H. S. Loewen; Brenda R. Hemmelgarn; Jaime M. Beecroft; Tanvir Chowdhury Turin; Patrick J. Hanly

STUDY OBJECTIVES Although restless legs syndrome (RLS) is common and well recognized as an important and potentially treatable cause of sleep disruption in end-stage renal disease (ESRD), few studies have evaluated the prevalence of RLS and its impact on sleep in the non-dialysis-dependent chronic kidney disease (CKD) population. The objectives of the study were to determine the prevalence of RLS across the full spectrum of kidney disease and to assess the impact of RLS on sleep quality and daytime function. METHODS Five hundred patients were recruited from nephrology clinics and were stratified according to estimated glomerular filtration rate (EGFR): eGFR ≥ 60 mL/min/1.73m(2) (n = 127), CKD (eGFR < 60, not on dialysis, n = 242), and ESRD (on hemodialysis, n = 131). All subjects completed a sleep and medical history questionnaire, an RLS questionnaire, the Pittsburgh Sleep Quality Index (PSQI), and the Epworth Sleepiness Scale (ESS). RESULTS The prevalence of RLS did not differ among the three groups (18.9% [eGFR ≥ 60], 26% (CKD), and 26% (ESRD) p = 0.27). However, many symptoms of sleep disruption were more common in patients with RLS, and RLS was independently correlated with the PSQI score both in the full cohort (OR = 2.63, CI = 1.60-4.00, p < 0.001) and the CKD group (OR = 2.39, CI = 1.20-4.79, p = 0.014). CONCLUSIONS RLS is common in non-dialysis-dependent CKD patients and is an important source of sleep disruption.


Chest | 2003

Oral Continuous Positive Airway Pressure for Sleep Apnea* Effectiveness, Patient Preference, and Adherence

Jaime M. Beecroft; Sandra Zanon; Dejan Lukic; Patrick J. Hanly

Collaboration


Dive into the Jaime M. Beecroft's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andreas Pierratos

Humber River Regional Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge